Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nextida GC is a specialized collagen peptide composition developed to target post-meal glucose spikes in a natural way. It is the first commercialized product from the Nextida platform by Rousselot (a brand of Darling Ingredients), designed as an innovative nutraceutical ingredient for metabolic health. Derived from hydrolyzed bovine collagen (primarily Type I & III), it has been shown in preclinical and clinical studies to significantly reduce postprandial blood glucose spikes when taken orally before meals—by an average of 42% in healthy individuals at doses of 5g or 10g. The mechanism involves supporting endogenous GLP-1 (glucagon-like peptide 1) production, leveraging the incretin effect to help manage blood sugar levels naturally. The ingredient is positioned for use in dietary supplements and functional foods aimed at metabolic wellness and glucose control[1][2][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nextida GC.